Hyderabad, India — September 18, 2025 — Sai Life Sciences has inaugurated Unit VI, a dedicated facility for the manufacture of Veterinary Active Pharmaceutical Ingredients (APIs) in Bidar, Karnataka. The new unit is located adjacent to their flagship API manufacturing site (Unit IV), and is built exclusively for veterinary applications, designed with global standards in safety, sustainability, and regulatory compliance to meet the rising global demand in animal health API supply.
Science Significance
Unit VI brings enhancements in manufacturing technology for veterinary APIs, enabling better process control, reduced contamination risks, and higher purity in API products. With stringent design and advanced engineering, the facility supports scalability, efficient yield, and minimized environmental footprint ‒ all critical for delivering APIs that meet pharmacopoeial and safety requirements for animals.
Regulatory Significance
The facility is constructed to comply with international veterinary regulatory standards, enabling products to access major markets requiring strict guidelines, such as Good Manufacturing Practice (GMP) and global veterinary pharmacopoeias. It strengthens the ability to satisfy regulatory audits and supply agreements, ensuring APIs produced fulfill safety, quality, and traceability norms demanded by animal health authorities.
Business Significance
Advertisement
By adding specialized capacity with Unit VI, Sai Life Sciences positions itself strongly in the growing animal health API market, tapping into increased demand for veterinary care, livestock health, and companion animal treatments. The facility allows the company to offer efficient, scalable production with lower lead times, making it a competitive supplier in high-value veterinary segments. This expansion diversifies their portfolio and enhances opportunities for global supply contracts.
Patients’ Significance
Although “patients” here refers to animal health, this development means veterinarians and pet owners may see more reliable, high-quality veterinary medicines. With APIs produced under stricter safety and consistency, treatments for animals are likely to become more effective and safer, with fewer adverse reactions. Improved supply stability may also reduce shortages of veterinary medicines.
Policy Significance
This investment aligns with policy trends that support animal health, public health, and agricultural biosecurity. Governments increasingly emphasize One Health approaches, ensuring animal well-being impacts human health via food safety and zoonotic disease prevention. Regulatory policy that encourages high-quality veterinary APIs and sustainable manufacturing is critical for responsible growth in this sector.
The opening of Unit VI signals a significant step forward in veterinary pharmaceutical manufacturing. By combining dedicated infrastructure, international safety and regulatory standards, and scalable operations, Sai Life Sciences is enhancing the supply chain for animal health APIs. This move is likely to support global animal healthcare, improve treatment access, and raise quality benchmarks. As veterinary medicine demand continues to grow, facilities like this will be central to reliable, safe, and sustainable API production.
Source: Sai Life Sciences Press Release
